Sied Kebir1,2,3, Laurèl Rauschenbach3,4, Martin Glas5,6,7,8, Manuel Weber9, Lazaros Lazaridis1,2,3, Teresa Schmidt1,2, Kathy Keyvani10, Niklas Schäfer11, Asma Milia12, Lale Umutlu13, Daniela Pierscianek4, Martin Stuschke14, Michael Forsting13, Ulrich Sure4, Christoph Kleinschnitz15, Gerald Antoch16, Patrick M Colletti17, Domenico Rubello18, Ken Herrmann9, Ulrich Herrlinger11, Björn Scheffler2,3, Ralph A Bundschuh19. 1. Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. 2. West German Cancer Center (WTZ), German Cancer Consortium (DKTK), University Hospital Essen, University Duisburg-Essen, Partner Site University Hospital Essen, Essen, Germany. 3. DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany. 4. Department of Neurosurgery and Spine Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 5. Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. martin.glas@uk-essen.de. 6. West German Cancer Center (WTZ), German Cancer Consortium (DKTK), University Hospital Essen, University Duisburg-Essen, Partner Site University Hospital Essen, Essen, Germany. martin.glas@uk-essen.de. 7. DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany. martin.glas@uk-essen.de. 8. Division of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany. martin.glas@uk-essen.de. 9. Department of Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 10. Institute of Neuropathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 11. Division of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany. 12. Department of Pulmonology and Cardiology, Petrus Hospital Academic Teaching, Wuppertal, Germany. 13. Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 14. Department of Radiotherapy, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 15. Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 16. Department of Diagnostic and Interventional Radiology, University Hospital Düsseldorf, University of Düsseldorf, Düsseldorf, Germany. 17. Department of Radiology, University of Southern California, Los Angeles, USA. 18. Department of Nuclear Medicine, Radiology, Neuroradiology, Clinical Pathology, S. Maria Della Misericordia Hospital, Rovigo, Italy. 19. Department of Nuclear Medicine, University Hospital Bonn, University of Bonn, Bonn, Germany.
Abstract
INTRODUCTION: This study aimed to test the diagnostic significance of FET-PET imaging combined with machine learning for the differentiation between multiple sclerosis (MS) and glioma II°-IV°. METHODS: Our database was screened for patients in whom FET-PET imaging was performed for the diagnostic workup of newly diagnosed lesions evident on MRI and suggestive of glioma. Among those, we identified patients with histologically confirmed glioma II°-IV°, and those who later turned out to have MS. For each group, tumor-to-brain ratio (TBR) derived features of FET were determined. A support vector machine (SVM) based machine learning algorithm was constructed to enhance classification ability, and Receiver Operating Characteristic (ROC) analysis with area under the curve (AUC) metric served to ascertain model performance. RESULTS: A total of 41 patients met selection criteria, including seven patients with MS and 34 patients with glioma. TBR values were significantly higher in the glioma group (TBRmax glioma vs. MS: p = 0.002; TBRmean glioma vs. MS: p = 0.014). In a subgroup analysis, TBR values significantly differentiated between MS and glioblastoma (TBRmax glioblastoma vs. MS: p = 0.0003, TBRmean glioblastoma vs. MS: p = 0.0003) and between MS and oligodendroglioma (ODG) (TBRmax ODG vs. MS: p = 0.003; TBRmean ODG vs. MS: p = 0.01). The ability to differentiate between MS and glioma II°-IV° increased from 0.79 using standard TBR analysis to 0.94 using a SVM based machine learning algorithm. CONCLUSIONS: FET-PET imaging may help differentiate MS from glioma II°-IV° and SVM based machine learning approaches can enhance classification performance.
INTRODUCTION: This study aimed to test the diagnostic significance of FET-PET imaging combined with machine learning for the differentiation between multiple sclerosis (MS) and glioma II°-IV°. METHODS: Our database was screened for patients in whom FET-PET imaging was performed for the diagnostic workup of newly diagnosed lesions evident on MRI and suggestive of glioma. Among those, we identified patients with histologically confirmed glioma II°-IV°, and those who later turned out to have MS. For each group, tumor-to-brain ratio (TBR) derived features of FET were determined. A support vector machine (SVM) based machine learning algorithm was constructed to enhance classification ability, and Receiver Operating Characteristic (ROC) analysis with area under the curve (AUC) metric served to ascertain model performance. RESULTS: A total of 41 patients met selection criteria, including seven patients with MS and 34 patients with glioma. TBR values were significantly higher in the glioma group (TBRmax glioma vs. MS: p = 0.002; TBRmean glioma vs. MS: p = 0.014). In a subgroup analysis, TBR values significantly differentiated between MS and glioblastoma (TBRmax glioblastoma vs. MS: p = 0.0003, TBRmean glioblastoma vs. MS: p = 0.0003) and between MS and oligodendroglioma (ODG) (TBRmax ODG vs. MS: p = 0.003; TBRmean ODG vs. MS: p = 0.01). The ability to differentiate between MS and glioma II°-IV° increased from 0.79 using standard TBR analysis to 0.94 using a SVM based machine learning algorithm. CONCLUSIONS: FET-PET imaging may help differentiate MS from glioma II°-IV° and SVM based machine learning approaches can enhance classification performance.
Authors: Paul Browne; Dhia Chandraratna; Ceri Angood; Helen Tremlett; Chris Baker; Bruce V Taylor; Alan J Thompson Journal: Neurology Date: 2014-09-09 Impact factor: 9.910
Authors: Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen Journal: Lancet Neurol Date: 2017-12-21 Impact factor: 44.182
Authors: G Balloy; J Pelletier; L Suchet; C Lebrun; M Cohen; P Vermersch; H Zephir; E Duhin; O Gout; R Deschamps; E Le Page; G Edan; P Labauge; C Carra-Dallieres; L Rumbach; E Berger; P Lejeune; P Devos; J-B N'Kendjuo; M Coustans; E Auffray-Calvier; B Daumas-Duport; L Michel; F Lefrere; D A Laplaud; C Brosset; P Derkinderen; J de Seze; S Wiertlewski Journal: J Neurol Date: 2018-07-27 Impact factor: 4.849
Authors: E E Pakos; P G Tsekeris; K Chatzidimou; A C Goussia; S Markoula; M I Argyropoulou; E G Pitouli; S Konitsiotis Journal: Clin Neurol Neurosurg Date: 2005-02 Impact factor: 1.876
Authors: Sied Kebir; Florian C Gaertner; Marcus Mueller; Michael Nelles; Matthias Simon; Niklas Schäfer; Moritz Stuplich; Christina Schaub; Michael Niessen; Frederic Mack; Ralph Bundschuh; Susanne Greschus; Markus Essler; Martin Glas; Ulrich Herrlinger Journal: Oncol Lett Date: 2016-02-04 Impact factor: 2.967
Authors: A S Jakola; A J Skjulsvik; K S Myrmel; K Sjåvik; G Unsgård; S H Torp; K Aaberg; T Berg; H Y Dai; K Johnsen; R Kloster; O Solheim Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Ian Law; Nathalie L Albert; Javier Arbizu; Ronald Boellaard; Alexander Drzezga; Norbert Galldiks; Christian la Fougère; Karl-Josef Langen; Egesta Lopci; Val Lowe; Jonathan McConathy; Harald H Quick; Bernhard Sattler; David M Schuster; Jörg-Christian Tonn; Michael Weller Journal: Eur J Nucl Med Mol Imaging Date: 2018-12-05 Impact factor: 9.236